Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Medical University of Vienna.
Recruitment status was  Recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: June 20, 2006
Last updated: September 14, 2007
Last verified: September 2007
The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.

Condition Intervention Phase
Procedure: echocardiography for intrapulmonary vasodilatation
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 100
Study Start Date: June 2006
Detailed Description:
Intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. Its diagnosis is established via contrast enhanced echocardiography. One used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. The purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 18 years
  • presence of liver cirrhosis
  • evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt

Exclusion Criteria:

  • inadequate echocardiographic image quality
  • allergies to echocardiographic contrast agents
  • pulmonary valve stenosis
  • pulmonary embolism
  • relevant tricuspid regurgitation
  • cardiomyopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00343122

Contact: Valentin Fuhrmann, MD 0043-1-40400 ext 4766
Contact: Peter Schenk, MD 0043-1-40400 ext 4766

Intensive Care Unit 13H1, Dep. of Internal Medicine IV, Medical University of Vienna Recruiting
Vienna, Austria, A-1090
Contact: Valentin Fuhrmann, MD    0043-1-40400 ext 4766   
Principal Investigator: Peter Schenk, MD         
Sub-Investigator: Valentin Fuhrmann, MD         
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Peter Schenk, MD Intensive Care Unit 13h1, Dep. of Internal Medicine IV, Medical University of Vienna
  More Information

Publications: Identifier: NCT00343122     History of Changes
Other Study ID Numbers: EK 4462005 
Study First Received: June 20, 2006
Last Updated: September 14, 2007
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:
hepatopulmonary syndrome

Additional relevant MeSH terms:
Liver Cirrhosis
Digestive System Diseases
Liver Diseases processed this record on May 26, 2016